Table 2.

Secondary Outcomes

Outcomea	Full Cohortb
	Adjusted OR (95% CI)	P value
Conversion to sinusc	1.1 (0.8 to 1.5)	.7
Bradycardiac	1.1 (0.7 to 1.6)	.7
Vasopressor duration, hr	−3.4 (−7.4 to 0.7)	.1
Length of stay, d
ICU	−0.3 (−1.5 to 0.9)	.6
Hospital	−1.7 (−3.8 to 0.4)	.1
Hospital deaths	1.0 (0.7 to 1.4)	.9

Receipt of phenylephrine (compared with norepinephrine) was not associated significantly with any secondary outcomes; there was no significant effect modification by baseline heart rate (P_interaction > .05 for all outcomes).

^aReference = norepinephrine.

^bTotal number of patients, 1,847 (norepinephrine, 946; phenylephrine, 901).

^cWithin a 6-h follow-up period.